Home / Companies / SNY / Catalysts / Page 3 Catalysts · SNY · CIK 1121404 · page 3 of 3 SNY catalysts and FDA events, page 3. Updated November 16, 2026 Snapshot 20261116T222116Z Built 2026-11-16 22:21 UTC
The next PDUFA date, the soonest catalysts with their source quotes and the latest FDA decisions are on SNY PDUFA dates and upcoming catalysts . This page continues the list.
Past catalysts and FDA decisions (continued) Date Drug Company Event Indication Status Source November 14, 2025 tolebrutinib (SAR442168) SNY Primary completion Primary Progressive Multiple Sclerosis Completed ClinicalTrials.gov October 23, 2025 sar444656 (kt-474) (SAR444656) SNY Primary completion Atopic Dermatitis Withdrawn ClinicalTrials.gov October 21, 2025 bivv020 (sar445088) (BIVV020) SNY Primary completion Transplant Rejection Completed ClinicalTrials.gov October 9, 2025 sar444656 (kt-474) (SAR444656) SNY Primary completion Hidradenitis Suppurativa Withdrawn ClinicalTrials.gov October 2, 2025 Cerezyme (imiglucerase) SNY Primary completion Gaucher's Disease Type III Completed ClinicalTrials.gov October 1, 2025 amlitelimab (SAR445229) SNY Primary completion Dermatitis Atopic Completed ClinicalTrials.gov September 28, 2025 tolebrutinib (SAR442168) SNY PDUFA date — Delayed SEC 8-K Exhibit 99.1 September 24, 2025 amlitelimab (SAR445229) SNY Primary completion Alopecia Areata Withdrawn ClinicalTrials.gov September 18, 2025 rsvt vaccine SNY Primary completion RSV Immunization Withdrawn ClinicalTrials.gov September 16, 2025 itepekimab (sar440340) (REGN3500) SNY Primary completion Bronchiectasis Completed ClinicalTrials.gov August 29, 2025 Wayrilz (rilzabrutinib) SNY FDA approval — Approved FDA Novel Drug Approvals August 29, 2025 Wayrilz (rilzabrutinib) SNY PDUFA date — Approved SEC 8-K Exhibit 99.1 August 21, 2025 amlitelimab (SAR445229) SNY Primary completion Dermatitis Atopic Completed ClinicalTrials.gov August 6, 2025 SAR447537 SNY Primary completion Alpha 1-Antitrypsin Deficiency; Emphysema Completed ClinicalTrials.gov July 23, 2025 amlitelimab (SAR445229) SNY Primary completion Dermatitis Atopic Completed ClinicalTrials.gov 2H 2025Half-year disclosed itepekimab (SAR440340) SNY Topline readout COPD in two phase 3 studies AERIFY-1 Scheduled SEC 8-K Exhibit 99.1 June 30, 2025 — SNY FDA approval — Approved SEC 8-K Exhibit 99.1 June 20, 2025 — SNY PDUFA date — Scheduled SEC 8-K Exhibit 99.1 June 18, 2025 SAR441566 SNY Primary completion Rheumatoid Arthritis Completed ClinicalTrials.gov June 11, 2025 low dose (ld) rsvt vaccine SNY Primary completion RSV Immunisation; Healthy Volunteers Withdrawn ClinicalTrials.gov June 11, 2025 doxercalciferol (gz427397) (GZ427397) SNY Primary completion Secondary Hyperparathyroidism-Chronic Kidney Disease Withdrawn ClinicalTrials.gov June 11, 2025 Doxercalciferol (doxercalciferol) SNY Label expansion — Approved openFDA Drugs@FDA March 28, 2025 Qfitlia™ (fitusiran) SNY FDA approval To prevent or reduce the frequency of bleeding episodes in hemophilia A or BPress Release Approved FDA Novel Drug Approvals February 14, 2025 Merilog (insulin aspart-szjj) SNY FDA approval — Approved openFDA Drugs@FDA October 25, 2024 Sarclisa (isatuximab-irfc) SNY Label expansion — Approved openFDA Drugs@FDA September 20, 2024 Sarclisa (isatuximab-irfc) SNY Label expansion — Approved openFDA Drugs@FDA Sep 2024Month disclosed — SNY FDA approval — Approved SEC 8-K Exhibit 99.1 June 10, 2024 Kevzara (sarilumab) SNY Label expansion — Approved openFDA Drugs@FDA March 7, 2024 Caprelsa (vandetanib) SNY Label expansion — Approved openFDA Drugs@FDA November 1, 2023 Sarclisa (isatuximab-irfc) SNY Label expansion — Approved openFDA Drugs@FDA October 23, 2023 Multaq (dronedarone hydrochloride) SNY Label expansion — Approved openFDA Drugs@FDA September 15, 2023 Nexviazyme (avalglucosidase alfa-ngpt) SNY Label expansion — Approved openFDA Drugs@FDA May 2023Month disclosed AYVAKIT® (avapritinib) SNY FDA approval advanced SM in June 2021 and indolent SM in May 2023 Approved SEC 8-K Exhibit 99.1 February 28, 2023 Kevzara (sarilumab) SNY Label expansion — Approved openFDA Drugs@FDA August 31, 2022 Xenpozyme (olipudase alfa-rpcp) SNY FDA approval — Approved FDA Novel Drug Approvals July 18, 2022 Clolar (clofarabine) SNY Label expansion — Approved openFDA Drugs@FDA August 6, 2021 Nexviazyme (avalglucosidase alfa-ngpt) SNY FDA approval — Approved openFDA Drugs@FDA July 30, 2021 Adlyxin (lixisenatide) SNY Label expansion — Approved openFDA Drugs@FDA July 16, 2021 Fexinidazole (fexinidazole) SNY FDA approval — Approved openFDA Drugs@FDA April 30, 2021 Aubagio (teriflunomide) SNY Label expansion — Approved openFDA Drugs@FDA March 31, 2021 Sarclisa (isatuximab-irfc) SNY Label expansion — Approved openFDA Drugs@FDA March 11, 2021 Fabrazyme (agalsidase beta) SNY Label expansion — Approved openFDA Drugs@FDA December 18, 2020 Jevtana Kit (cabazitaxel) SNY Label expansion — Approved openFDA Drugs@FDA November 12, 2020 Fexinidazole (fexinidazole) SNY Complete Response Letter — CRL issued FDA Complete Response Letters March 12, 2020 Thyrogen (thyrotropin alfa) SNY Label expansion — Approved openFDA Drugs@FDA March 2, 2020 Sarclisa (isatuximab-irfc) SNY FDA approval — Approved openFDA Drugs@FDA December 11, 2017 Admelog (insulin lispro) SNY FDA approval — Approved openFDA Drugs@FDA May 22, 2017 Kevzara (sarilumab) SNY FDA approval — Approved openFDA Drugs@FDA November 21, 2016 Soliqua 100/33 (insulin glargine; lixisenatide) SNY FDA approval — Approved openFDA Drugs@FDA July 27, 2016 Adlyxin (lixisenatide) SNY FDA approval — Approved openFDA Drugs@FDA
FDA calendar PDUFA dates PDUFA calendar AdCom calendar FDA approvals today CRL tracker PDUFA outcomes dataset Indications Every catalyst is quoted from SNY’s SEC filings, FDA records or ClinicalTrials.gov; each row links its primary source. Dates move; the linked filing is authoritative. Not investment advice.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.